AUM Pharmacy
Health Hub
Search Icon

AUM Pharmacy

Hi there!

Hello, Login
All Categories
VisaVisaVisa
slide-0
slide-1
slide-2
slide-3

Sitasto M 50/500 Tablet PR

Prescription Icon
Prescription Required

Marketer

Acugen Lifesciences Pvt Ltd

Salt Composition

Sitagliptin (50mg) + Metformin (500mg)

Overview Sitasto M 50/500 Tablet PR

Diabex Duo 50/500mg tablets combine two medications to effectively manage elevated blood glucose in individuals with type 2 diabetes. This dual action helps mitigate severe diabetic complications like renal impairment and vision loss, potentially lessening the risk of cardiovascular events. Diabex Duo may be administered independently or in conjunction with other antidiabetic therapies. Optimal results are achieved with a balanced diet and regular physical activity. Dosage is individualized based on your health status, glucose levels, and current medications. Consuming this medication with food minimizes gastrointestinal discomfort. Consistent daily dosing at the same time maximizes therapeutic benefit; discontinuation should only occur under medical guidance. Adherence to your prescribed diet and exercise regimen is crucial for diabetes control. Lifestyle modifications significantly impact diabetes management. Common side effects include diarrhea, nausea, vomiting, indigestion, headache, and pharyngitis. Hypoglycemia is a potential adverse effect when used with insulin or sulfonylureas; learn to identify and manage this condition. This medication is not universally suitable. Inform your physician of any pre-existing kidney, liver, or heart conditions, pancreatic issues, or excessive alcohol consumption before starting treatment. Pregnant or lactating individuals require medical consultation prior to use. Drug interactions are possible; disclose all medications to your doctor for safety. Alcohol should be limited due to its hypoglycemic effect. Your doctor will monitor your renal function and blood glucose levels throughout treatment.

Uses of Sitasto M 50/500 Tablet PR

Managing Type 2 Diabetes

Major Benefits of Sitasto M 50/500 Tablet PR:

Follow your physician's instructions or consult the product label for usage guidelines. Administer Sitasto M 50/500 Tablet PR with a meal.

Common Side effects of Sitasto M 50/500 Tablet PR:

  • Decreased appetite
  • Vomiting
  • Upper respiratory tract infection
  • Hypoglycemia (low blood glucose level)
  • Abdominal bloating
  • Nausea
  • Diarrhea

How to use Sitasto M 50/500 Tablet PR:

Follow your physician's instructions or consult the product labeling for dosage guidance. Administer Sitasto M 50/500 Tablet PR with a meal.

How Sitasto M 50/500 Tablet PR works:

Sitasto M 50/500 Tablet PR combines sitagliptin and metformin to manage blood glucose levels. Sitagliptin enhances insulin production by the pancreas, improves insulin utilization, and reduces hepatic glucose output. Metformin, a biguanide, works by decreasing liver glucose production, slowing intestinal glucose absorption, and boosting insulin sensitivity. This dual action results in superior glycemic control.

SAFETY ADVICE

AlcoholAlcoholUNSAFE

Consuming alcohol alongside Sitasto M 50/500 Tablet PR is inadvisable.

PregnancyPregnancyCONSULT YOUR DOCTOR

The use of Sitasto M 50/500 Tablet PR during pregnancy may pose risks. While human data is scarce, animal research indicates potential harm to the fetus. A physician will assess the advantages against possible dangers prior to prescribing. Seek medical advice.

Breast feedingBreast feedingCONSULT YOUR DOCTOR

Using Sitasto M 50/500 Tablet PR while breastfeeding is likely inadvisable. Available human data indicates potential drug transfer to breast milk, posing a possible risk to the infant.

DrivingDrivingCAUTION

Driving may be impaired by excessively high or low blood glucose levels. Refrain from driving if such symptoms arise.

KidneyKidneyCAUTION

Patients with kidney impairment should use Sitasto M 50/500 Tablet PR cautiously, potentially requiring dosage modification. Consultation with a physician is recommended. In cases of severe kidney disease, Sitasto M 50/500 Tablet PR is contraindicated. Routine monitoring of renal function is advised during treatment.

LiverLiverUNSAFE

Individuals with liver impairment should likely refrain from using Sitasto M 50/500 Tablet PR due to potential safety concerns. Medical advice is recommended.

What if you forget to take Sitasto M 50/500 Tablet PR :

Should you forget a dose of Sitasto M 50/500 Tablet PR, administer it at your earliest convenience. Nevertheless, if your next scheduled dose is imminent, omit the missed dose and resume your usual dosing regimen. Avoid taking a double dose.

Facts to Know About Sitasto M 50/500 Tablet PR

LabelValue
Potential for Dependence None.
Treatment Category Medication for diabetes

FAQs on Sitasto M 50/500 Tablet PR

Sitagliptin and Metformin, combined as Sitasto M 50/500 Tablet PR, treat type 2 diabetes mellitus in adults. This medication enhances blood sugar control when used with a healthy diet and regular physical activity. Metformin reduces hepatic glucose production and improves insulin responsiveness. Sitagliptin's action involves DPP4 enzyme inhibition, stimulating pancreatic insulin secretion. This formulation is unsuitable for individuals under 18.
Prolonged Sitasto M 50/500 Tablet PR use can indeed lead to vitamin B12 deficiency. This medication impedes the stomach's absorption of vitamin B12. Consequently, untreated deficiency may result in anemia and neurological complications, potentially manifesting as numbness and tingling in extremities, muscular weakness, urinary dysfunction, cognitive changes, and impaired balance. To mitigate these risks, supplemental vitamin B12 is recommended by some experts at least annually.
Sitasto M 50/500 Tablet PR may cause common side effects including low blood sugar (hypoglycemia), taste changes, nausea, abdominal pain, diarrhea, headache, and upper respiratory infections. Rare but serious side effects such as lactic acidosis are also possible. Prolonged use may result in vitamin B12 deficiency.
Patients with hypersensitivity to any constituent or inactive ingredient in Sitasto M 50/500 Tablet PR should not use this medication. Furthermore, its administration is contraindicated in individuals with significantly compromised renal or hepatic function, congestive heart failure, lactic acidosis, or diabetic ketoacidosis.
Combining Sitasto M 50/500 Tablet PR with alcohol is unsafe and may heighten the risk of lactic acidosis.
Retain this medication within its original, sealed container. Follow the storage guidelines provided on the packaging or label. Discard any remaining medicine. Ensure it remains inaccessible to children, pets, and others.
Sitagliptin/metformin combination therapy (such as Sitasto M 50/500 Tablet PR) carries a risk of lactic acidosis, a serious medical condition characterized by excessive blood lactic acid. This rare complication, also termed metformin-associated lactic acidosis (MALA), necessitates avoidance of this medication in individuals with impaired kidney function, advanced age, or significant alcohol consumption. Symptoms potentially indicative of lactic acidosis include muscular discomfort or weakness, lightheadedness, fatigue, cold extremities, respiratory distress, nausea, emesis, abdominal pain, and bradycardia. Should these symptoms develop, discontinue Sitagliptin/Metformin and seek prompt medical attention.
Sitasto M 50/500 Tablet PR combines sitagliptin and metformin to manage type 2 diabetes mellitus in adults. This medication enhances blood sugar control when used with a suitable diet and exercise regimen. Metformin reduces hepatic glucose production and improves insulin responsiveness. Sitagliptin's action involves DPP4 enzyme inhibition, boosting pancreatic insulin secretion. This formulation is unsuitable for individuals under 18.
Sitasto M 50/500 Tablet PR may cause common side effects including low blood sugar (hypoglycemia), taste changes, nausea, abdominal pain, diarrhea, headache, and upper respiratory infections. Rare but serious side effects such as lactic acidosis are also possible. Prolonged use might result in vitamin B12 deficiency.
Patients with hypersensitivity to any constituent of Sitasto M 50/500 Tablet PR should not take this medication. Similarly, its administration is contraindicated in individuals with severely compromised renal or hepatic function, congestive cardiac failure, lactic acidosis, or diabetic ketoacidosis.
Consuming alcohol concurrently with Sitasto M 50/500 Tablet PR is unsafe due to a heightened risk of lactic acidosis.
Indeed, Sitasto M 50/500 Tablet PR carries a risk of lactic acidosis, a serious medical condition characterized by excessive blood lactic acid. This adverse reaction, also termed Metformin-associated lactic acidosis (MALA), is uncommon but warrants caution. Consequently, its use is contraindicated in individuals with impaired kidney function, the elderly, and those consuming significant alcohol. Lactic acidosis symptoms can encompass muscle aches or weakness, vertigo, fatigue, cold extremities, dyspnea, nausea, emesis, abdominal discomfort, and bradycardia. Should these symptoms arise, discontinue Sitagliptin + Metformin immediately and seek prompt medical attention.
Prolonged Sitasto M 50/500 Tablet PR use can indeed lead to Vitamin B12 deficiency by hindering its gastric absorption. This deficiency, if left unaddressed, may manifest as anemia, neurological complications including peripheral neuropathy (tingling, numbness in extremities), weakness, urinary dysfunction, cognitive changes, and gait instability. To mitigate these risks, supplemental Vitamin B12 intake, at least annually, has been proposed by some studies.
Maintain this medication within its original, securely sealed container. Follow the storage guidelines provided on the packaging. Discard any leftover medication. Prevent access by children, pets, and other individuals.
Sitasto M 50/500 Tablet PR combines sitagliptin and metformin to manage type 2 diabetes mellitus in adults. This medication enhances blood sugar control when coupled with a healthy diet and regular physical activity. Metformin reduces liver glucose output and improves insulin responsiveness. Sitagliptin blocks DPP4, boosting pancreatic insulin secretion. This formulation is unsuitable for individuals under 18.
Sitasto M 50/500 Tablet PR may cause common side effects including low blood sugar (hypoglycemia), taste disturbances, nausea, abdominal pain, diarrhea, headache, and upper respiratory infections. Rare but serious adverse events such as lactic acidosis are also possible. Prolonged administration may result in vitamin B12 deficiency.
Patients with hypersensitivity to Sitasto M 50/500 Tablet PR constituents or inactive ingredients should not use this medication. Similarly, its administration is contraindicated in individuals experiencing severe renal or hepatic dysfunction, congestive heart failure, lactic acidosis, or diabetic ketoacidosis.
Combining Sitasto M 50/500 Tablet PR with alcohol is unsafe and may heighten the risk of lactic acidosis.
Indeed, Sitasto M 50/500 Tablet PR carries a risk of lactic acidosis, a serious medical condition characterized by excessive blood lactic acid. This complication, also termed MALA (Metformin-associated lactic acidosis), is infrequent but warrants caution. Consequently, its use is contraindicated in individuals with pre-existing kidney impairment, the elderly, or those consuming substantial alcohol. Potential symptoms include muscular discomfort or weakness, vertigo, fatigue, peripheral coldness, respiratory distress, emesis, nausea, abdominal pain, and bradycardia. Should these symptoms arise, discontinue Sitagliptin + Metformin immediately and seek medical attention.
Prolonged use of Sitasto M 50/500 Tablet PR can indeed lead to vitamin B12 deficiency. This medication disrupts the body's absorption of vitamin B12 within the gastrointestinal tract. Consequently, untreated deficiency may manifest as anemia and neurological complications, including paresthesia in the extremities, generalized weakness, urinary dysfunction, cognitive impairment, and ataxia. Preventive measures, according to some studies, include supplemental vitamin B12 administration at least annually.
Retain this medication in its original, sealed container or packaging. Follow the storage instructions provided on the packaging or label. Discard any leftover medication. Prevent access by children, pets, and others.
Sitasto M 50/500 Tablet P...
123
MRP 143
13% off